PDF(Pubmed)
Abstract：
UNASSIGNED: We present a case of a patient with preceding vitreomacular traction (VMT) who developed a full-thickness macular hole (FTMH) following his sixth intravitreal aflibercept injection for the treatment of age-related macular degeneration and review the literature on risk factors and pathogenesis of this adverse event.
UNASSIGNED: FTMH can occur after an extended number of repeat intravitreal injections in the setting of worsening vitreomacular adhesion or VMT. This patient\'s FTMH was successfully treated surgically in a timely manner, and additional injections were resumed safely.
UNASSIGNED: Patients with an unexpected decrease in vision after intravitreal injections should be reevaluated with optical coherence tomography to rule out alternative pathology including vitreomacular interface abnormalities. FTMH, if present, should be treated promptly to allow for resumption of therapy as needed and visual optimization.
UNASSIGNED: FTMH can occur after an extended number of repeat intravitreal injections in the setting of worsening vitreomacular adhesion or VMT. This patient\'s FTMH was successfully treated surgically in a timely manner, and additional injections were resumed safely.
UNASSIGNED: Patients with an unexpected decrease in vision after intravitreal injections should be reevaluated with optical coherence tomography to rule out alternative pathology including vitreomacular interface abnormalities. FTMH, if present, should be treated promptly to allow for resumption of therapy as needed and visual optimization.
摘要：
■我们介绍了一例玻璃体黄斑牵引（VMT）患者，他在第六次玻璃体内注射阿柏西普治疗年龄相关性黄斑变性后出现了全厚度黄斑裂孔（FTMH），并回顾了有关该不良事件的危险因素和发病机制的文献。
■FTMH可在玻璃体黄斑粘连或VMT恶化的情况下重复多次玻璃体内注射后发生。该患者的FTMH及时手术治疗成功，并安全恢复额外的注射.
■玻璃体内注射后视力意外下降的患者，应该用光学相干断层扫描重新评估，以排除包括玻璃体黄斑界面异常在内的替代病理。FTMH,如果存在，应及时治疗，以便根据需要恢复治疗和视觉优化。
■FTMH可在玻璃体黄斑粘连或VMT恶化的情况下重复多次玻璃体内注射后发生。该患者的FTMH及时手术治疗成功，并安全恢复额外的注射.
■玻璃体内注射后视力意外下降的患者，应该用光学相干断层扫描重新评估，以排除包括玻璃体黄斑界面异常在内的替代病理。FTMH,如果存在，应及时治疗，以便根据需要恢复治疗和视觉优化。
